Chemotherapy for pilocytic astrocytomas

Mark T. Brown, Henry S. Friedman, Beverley Hockenberger, W. Jerry Oakes, Orest Boyko, S. Clifford Schold

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Background. Although pilocytic astrocytomas (PA) generally are considered benign, a subset of patients with PA have disease progression despite standard treatment with surgery and radiation therapy. The authors report their experience with chemotherapy in this patient group. Methods. The authors treated 11 patients (4 males and 7 females; median age at diagnosis, 8 years) with pathologically confirmed PA with chemotherapy. In eight patients, tumor progression or recurrence despite prior surgery and radiation therapy led to chemotherapy treatment. In three children younger than 5 years, chemotherapy was given in lieu of radiation therapy immediately after diagnosis (in one patient) or at the time of disease progression after surgery (in two patients). The authors used ten different chemotherapy regimens to treat the 11 patients. Results. Chemotherapy produced clinical and radiographic improvement (R/R) in four (36%) patients, clinical stabilization and radiographic improvement (SD/R) in 1 (9%), clinical and radiographic stabilization (SD/SD) in 3 (27%), and was associated with clinical and radiographic progression (PD/PD) in 3 (27%). Three of the five patients with radiographic improvement had a greater than 75% reduction of maximal cross‐sectional tumor area. Hematologic toxicity resulted in dose reductions in 43 of 110 (39%) total courses of chemotherapy. There were three hospital admissions for fever and neutropenia and one chemotherapy‐related death. Conclusions. The authors conclude that chemotherapy may benefit those with progressive inoperable PA. Chemotherapy may delay the need for radiation therapy in young patients with unresectable PA requiring treatment. PA may be a chemosensitive primary brain tumor.

Original languageEnglish (US)
Pages (from-to)3165-3172
Number of pages8
JournalCancer
Volume71
Issue number10
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Astrocytoma
Drug Therapy
Radiotherapy
Disease Progression
Neutropenia
Brain Neoplasms
Neoplasms
Fever
Therapeutics
Recurrence

Keywords

  • astrocytoma
  • chemotherapy
  • glioma
  • pilocytic astrocytoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Brown, M. T., Friedman, H. S., Hockenberger, B., Oakes, W. J., Boyko, O., & Schold, S. C. (1993). Chemotherapy for pilocytic astrocytomas. Cancer, 71(10), 3165-3172. https://doi.org/10.1002/1097-0142(19930515)71:10<3165::AID-CNCR2820711044>3.0.CO;2-N

Chemotherapy for pilocytic astrocytomas. / Brown, Mark T.; Friedman, Henry S.; Hockenberger, Beverley; Oakes, W. Jerry; Boyko, Orest; Schold, S. Clifford.

In: Cancer, Vol. 71, No. 10, 1993, p. 3165-3172.

Research output: Contribution to journalArticle

Brown, MT, Friedman, HS, Hockenberger, B, Oakes, WJ, Boyko, O & Schold, SC 1993, 'Chemotherapy for pilocytic astrocytomas', Cancer, vol. 71, no. 10, pp. 3165-3172. https://doi.org/10.1002/1097-0142(19930515)71:10<3165::AID-CNCR2820711044>3.0.CO;2-N
Brown MT, Friedman HS, Hockenberger B, Oakes WJ, Boyko O, Schold SC. Chemotherapy for pilocytic astrocytomas. Cancer. 1993;71(10):3165-3172. https://doi.org/10.1002/1097-0142(19930515)71:10<3165::AID-CNCR2820711044>3.0.CO;2-N
Brown, Mark T. ; Friedman, Henry S. ; Hockenberger, Beverley ; Oakes, W. Jerry ; Boyko, Orest ; Schold, S. Clifford. / Chemotherapy for pilocytic astrocytomas. In: Cancer. 1993 ; Vol. 71, No. 10. pp. 3165-3172.
@article{1a812411e5574b24a2d765520421bcb0,
title = "Chemotherapy for pilocytic astrocytomas",
abstract = "Background. Although pilocytic astrocytomas (PA) generally are considered benign, a subset of patients with PA have disease progression despite standard treatment with surgery and radiation therapy. The authors report their experience with chemotherapy in this patient group. Methods. The authors treated 11 patients (4 males and 7 females; median age at diagnosis, 8 years) with pathologically confirmed PA with chemotherapy. In eight patients, tumor progression or recurrence despite prior surgery and radiation therapy led to chemotherapy treatment. In three children younger than 5 years, chemotherapy was given in lieu of radiation therapy immediately after diagnosis (in one patient) or at the time of disease progression after surgery (in two patients). The authors used ten different chemotherapy regimens to treat the 11 patients. Results. Chemotherapy produced clinical and radiographic improvement (R/R) in four (36{\%}) patients, clinical stabilization and radiographic improvement (SD/R) in 1 (9{\%}), clinical and radiographic stabilization (SD/SD) in 3 (27{\%}), and was associated with clinical and radiographic progression (PD/PD) in 3 (27{\%}). Three of the five patients with radiographic improvement had a greater than 75{\%} reduction of maximal cross‐sectional tumor area. Hematologic toxicity resulted in dose reductions in 43 of 110 (39{\%}) total courses of chemotherapy. There were three hospital admissions for fever and neutropenia and one chemotherapy‐related death. Conclusions. The authors conclude that chemotherapy may benefit those with progressive inoperable PA. Chemotherapy may delay the need for radiation therapy in young patients with unresectable PA requiring treatment. PA may be a chemosensitive primary brain tumor.",
keywords = "astrocytoma, chemotherapy, glioma, pilocytic astrocytoma",
author = "Brown, {Mark T.} and Friedman, {Henry S.} and Beverley Hockenberger and Oakes, {W. Jerry} and Orest Boyko and Schold, {S. Clifford}",
year = "1993",
doi = "10.1002/1097-0142(19930515)71:10<3165::AID-CNCR2820711044>3.0.CO;2-N",
language = "English (US)",
volume = "71",
pages = "3165--3172",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Chemotherapy for pilocytic astrocytomas

AU - Brown, Mark T.

AU - Friedman, Henry S.

AU - Hockenberger, Beverley

AU - Oakes, W. Jerry

AU - Boyko, Orest

AU - Schold, S. Clifford

PY - 1993

Y1 - 1993

N2 - Background. Although pilocytic astrocytomas (PA) generally are considered benign, a subset of patients with PA have disease progression despite standard treatment with surgery and radiation therapy. The authors report their experience with chemotherapy in this patient group. Methods. The authors treated 11 patients (4 males and 7 females; median age at diagnosis, 8 years) with pathologically confirmed PA with chemotherapy. In eight patients, tumor progression or recurrence despite prior surgery and radiation therapy led to chemotherapy treatment. In three children younger than 5 years, chemotherapy was given in lieu of radiation therapy immediately after diagnosis (in one patient) or at the time of disease progression after surgery (in two patients). The authors used ten different chemotherapy regimens to treat the 11 patients. Results. Chemotherapy produced clinical and radiographic improvement (R/R) in four (36%) patients, clinical stabilization and radiographic improvement (SD/R) in 1 (9%), clinical and radiographic stabilization (SD/SD) in 3 (27%), and was associated with clinical and radiographic progression (PD/PD) in 3 (27%). Three of the five patients with radiographic improvement had a greater than 75% reduction of maximal cross‐sectional tumor area. Hematologic toxicity resulted in dose reductions in 43 of 110 (39%) total courses of chemotherapy. There were three hospital admissions for fever and neutropenia and one chemotherapy‐related death. Conclusions. The authors conclude that chemotherapy may benefit those with progressive inoperable PA. Chemotherapy may delay the need for radiation therapy in young patients with unresectable PA requiring treatment. PA may be a chemosensitive primary brain tumor.

AB - Background. Although pilocytic astrocytomas (PA) generally are considered benign, a subset of patients with PA have disease progression despite standard treatment with surgery and radiation therapy. The authors report their experience with chemotherapy in this patient group. Methods. The authors treated 11 patients (4 males and 7 females; median age at diagnosis, 8 years) with pathologically confirmed PA with chemotherapy. In eight patients, tumor progression or recurrence despite prior surgery and radiation therapy led to chemotherapy treatment. In three children younger than 5 years, chemotherapy was given in lieu of radiation therapy immediately after diagnosis (in one patient) or at the time of disease progression after surgery (in two patients). The authors used ten different chemotherapy regimens to treat the 11 patients. Results. Chemotherapy produced clinical and radiographic improvement (R/R) in four (36%) patients, clinical stabilization and radiographic improvement (SD/R) in 1 (9%), clinical and radiographic stabilization (SD/SD) in 3 (27%), and was associated with clinical and radiographic progression (PD/PD) in 3 (27%). Three of the five patients with radiographic improvement had a greater than 75% reduction of maximal cross‐sectional tumor area. Hematologic toxicity resulted in dose reductions in 43 of 110 (39%) total courses of chemotherapy. There were three hospital admissions for fever and neutropenia and one chemotherapy‐related death. Conclusions. The authors conclude that chemotherapy may benefit those with progressive inoperable PA. Chemotherapy may delay the need for radiation therapy in young patients with unresectable PA requiring treatment. PA may be a chemosensitive primary brain tumor.

KW - astrocytoma

KW - chemotherapy

KW - glioma

KW - pilocytic astrocytoma

UR - http://www.scopus.com/inward/record.url?scp=0027172658&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027172658&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19930515)71:10<3165::AID-CNCR2820711044>3.0.CO;2-N

DO - 10.1002/1097-0142(19930515)71:10<3165::AID-CNCR2820711044>3.0.CO;2-N

M3 - Article

VL - 71

SP - 3165

EP - 3172

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -